- Zacks•2 days ago
Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.
- PR Newswire•3 days agoAgenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors
LEXINGTON, Mass., Nov. 30, 2016 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-OX40 agonist antibody INCAGN1949. The trial is being conducted by, and in collaboration with, Incyte Corporation. "We are pleased with the progress of our fruitful alliance with Incyte and also anticipate advancing a number of Agenus programs outside of the Incyte collaboration, such as our PD-1 antagonist, AGEN2034, into clinical development in the coming months," said Garo H. Armen, Ph.D. Chairman and CEO of Agenus.
AGEN : Summary for Agenus Inc. - Yahoo Finance
Agenus Inc. (AGEN)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||3.60 x 1000|
|Ask||4.29 x 300|
|Day's Range||3.93 - 4.21|
|52 Week Range||2.61 - 7.49|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.04|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|